Dimerix Limited (AU:DXB)
ASX:DXB
Want to see AU:DXB full AI Analyst Report?
DXB Stock Chart & Stats
AU$0.40
-AU$0.03(-5.00%)
At close: 4:00 PM EST
AU$0.40
-AU$0.03(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.18 - AU$0.67
Previous CloseN/A
Volume4.60M
Average Volume (3M)1.47M
Market Cap
AU$111.07M
Enterprise ValueAU$72.62M
Total Cash (Recent Filing)AU$38.49M
Total Debt (Recent Filing)AU$33.42K
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding600,396,800
10 Day Avg. Volume1,720,426
30 Day Avg. Volume1,468,144
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)24.09
Price to Sales (P/S)256.86
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$18.30M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 70% revenue expansion represents durable top-line momentum for a biotech developing clinical-stage assets. Sustained revenue growth can extend the company’s runway, support continued R&D investment and partnerships, and provide objective validation of product or service traction that underpins long-term value creation if costs are managed.
Low Financial LeverageA near-zero debt-to-equity ratio provides structural financial resilience for a development-stage biopharma. Minimal leverage reduces bankruptcy and interest burden risks, preserves optionality for milestone financing or licensing, and gives management flexibility to fund trials or strategic initiatives without onerous fixed obligations.
Cash ConversionAn operating cash flow to net income ratio above 1 indicates solid cash conversion despite reported losses. Durable cash generation relative to accounting profits improves the company’s ability to fund operations and clinical programs internally for longer, reducing short-term refinancing pressure and supporting execution of development milestones.
Bears Say
Negative ProfitabilityMaterial negative net and EBIT margins show the company is not generating operating profits and faces structural cost challenges. Persistent unprofitability implies ongoing need for external funding, constrains reinvestment capacity, and requires either sustained margin improvement or transformative revenue mix changes to achieve durable profitability.
Very Negative ROEA deeply negative return on equity signals that existing capital is producing large accounting losses and destroying shareholder value. This points to capital inefficiency and a high bar for management to demonstrate a credible path to positive returns, which is critical for long-term investor confidence and sustainable capital access.
Declining Free Cash FlowA more than 300% decline in free cash flow growth represents a severe deterioration in the company’s ability to generate surplus cash. For a clinical-stage biotech this raises medium-term funding and dilution risk, weakens the internal funding runway for trials, and increases reliance on capital markets or partners to sustain operations.
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.17 and its highest was AU$0.67 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$111.07M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Sep 02, 2026 which is in 92 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.027.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Overvalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.409%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.10%
12-Months-Change
Fundamentals
Return on Equity
-278.87%
Trailing 12-Months
Asset Growth
194.65%
Trailing 12-Months
Company Description
Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Orthocell Ltd
―
Immutep Ltd
―
Race Oncology Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---